文献速递神经肿瘤神经重症

贝伐珠单抗难治性高级别胶质瘤再程放疗联合贝伐珠单抗及米诺环素的前瞻性1期试验

Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial.
PubMed 文献 · J Neurooncol · 2020-06-06

针对放疗、替莫唑胺和贝伐珠单抗治疗后进展的高级别胶质瘤患者,该1期试验采用3+3剂量递增设计并扩展10人,评估再程放疗、米诺环素和贝伐珠单抗的安全性及对生存、症状负担和神经认知功能的影响。米诺环素最大耐受剂量为400mg每日两次,未出现意外毒性,PFS3为64.6%,中位总生存期6.4个月,治疗完成至肿瘤进展期间症状负担和神经认知功能未下降。

要点

  • 米诺环素400mg每日两次联合贝伐珠单抗和再程放疗耐受性良好。
  • PFS3为64.6%,中位总生存期为6.4个月。
  • 治疗完成至肿瘤进展期间症状负担和神经认知功能未下降。

核心结论

  • 米诺环素400mg口服每日两次联合贝伐珠单抗和再程放疗在贝伐珠单抗进展的胶质瘤患者中耐受性良好。

研究设计与样本

  • 1期试验采用3+3设计进行剂量递增,随后进行10人剂量扩展。

主要发现

  • 米诺环素最大耐受剂量为400mg每日两次,未出现意外毒性。
  • PFS3为64.6%,中位总生存期为6.4个月。
  • 治疗完成至肿瘤进展期间症状负担和神经认知功能未下降。

关键数值与推荐

  • 贝伐珠单抗剂量为10mg/kg静脉注射每两周一次。
  • 米诺环素最大耐受剂量为400mg每日两次口服。

临床怎么用

  • 对于贝伐珠单抗治疗后进展的高级别胶质瘤患者,可考虑再程放疗联合贝伐珠单抗和米诺环素400mg每日两次作为耐受性良好的治疗方案。

局限性

  • 样本量小,为1期试验,需进一步验证疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There are no effective treatments for gliomas after progression on radiation, temozolomide, and bevacizumab. Microglia activation may be involved in radiation resistance and can be inhibited by the brain penetrating antibiotic minocycline. In this phase 1 trial, we examined the safety and effect on survival, symptom burden, and neurocognitive function of reirradiation, minocycline, and bevacizumab. METHODS: The trial used a 3 + 3 design for dose escalation followed by a ten person dose expansion. Patients received reirradiation with dosing based on radiation oncologist judgment, bevacizumab 10 mg/kg IV every two weeks, and oral minocycline twice a day. Symptom burden was measured using MDASI-BT. Neurocognitive function was measured using the COGSTATE battery. RESULTS: The maximum tolerated dose of minocycline was 400 mg twice a day with no unexpected toxicities. The PFS3 was 64.6%, and median overall survival was 6.4 months. Symptom burden and neurocognitive function did not decline in the interval between treatment completion and tumor progression. CONCLUSIONS: Minocycline 400 mg orally twice a day with bevacizumab and reirradiation is well tolerated by physician and patient reported outcomes in people with gliomas that progress on bevacizumab.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Cohen AL, Anker CJ, Johnson B, et al. Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol. 2020. PMID: 32506371. doi:10.1007/s11060-020-03551-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。